DEVELOPING A NEW APPROACH TO METASTATIC CANCER

LifeBridge Innovations is developing the investigational LB10000, a programmable Tumor Treating Fields platform designed to dynamically target multiple sites of metastatic disease. Following completion of a GLP large-animal safety study delivering more than 2,700 hours of therapy, LifeBridge is advancing the system toward first-in-human clinical evaluation.

 

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

OUR SOLUTION

Our patented programmable array architecture allows individual transducers to be dynamically configured to direct Tumor Treating Fields toward multiple treatment regions.    

LEARN MORE→

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

THE SCIENCE

Tumor Treating Fields use alternating electric fields to disrupt electrically charged structures involved in cancer cell division.

LEARN MORE→

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

ABOUT

We started by trying to save one life and discovered the potential to impact millions. 

LEARN MORE→

LifeBridge Innovations’ dynamic delivery of TTF provides the capability to treat cancer in multiple locations in the body simultaneously, allowing us to offer TTF to Stage IV patients who would otherwise have few options left.​

​

Learn More

Cancer remains one of the world’s leading causes of death, with millions of new cases diagnosed each year. In the U.S. alone, over 1,600 people lose their lives to cancer daily. For many patients, current treatments—surgery, chemotherapy, and radiation—can eventually fail, especially in advanced stages when the disease becomes recurrent and treatment-resistant. Tumor Treating Fields(TTF) have emerged as a promising treatment modality in cancer care. First introduced by Novocure, TTF has been recognized as a standard of care for glioblastoma by the National Comprehensive Cancer Network. However, current static TTF systems are designed to treat tumors in a single location and are limited in their ability to address diffuse metastatic disease. At LifeBridge Innovations, we are advancing the next generation of TTF therapy through our dynamic, programmable LB10000 system. Unlike static delivery, our adaptive platform is designed to target multiple areas of the body simultaneously—offering new hope for Stage IV patients with widespread metastatic disease.​